Skip to main content

Table 2 Outcomes in the cohort

From: The influence of statin exposure on inflammatory markers in patients with early bacterial infection: pilot prospective cohort study

Outcome

Combined (n = 209)

Statin (n = 58)

Non-statin (n = 151)

p-value1

Death by day 10 (n,%)

5 (2.4)

2 (3.5)

3 (2.0)

0.62

HDU/ICU admission (n,%)

7 (3.3)

2 (3.4)

5 (3.3)

1.00

HDU/ICU admission by day 10 (n,%)

8 (3.8)

3 (5.2)

5 (3.3)

0.69

Status at 30 days

   

0.069

Dead

12 (5.7)

3 (5.2)

9 (6.0)

 

In ICU/HDU

1 (0.48)

0 (0)

1 (0.66)

 

In ward

27 (12.9)

13 (22.4)

14 (9.3)

 

Discharged from hospital

169 (80.9)

42 (72.4)

127 (84.1)

 

More SIRS criteria at any time than recorded on day 1 (n,%)

76 (37.3)

27 (47.4)

49 (33.3)

0.063

Supplemental oxygen, days 2–10 (n,%)

96 (47.1)

30 (52.6)

66 (44.9)

0.32

Days on supplemental oxygen (median [IQR]), days 1–10

1 (0–3)

1 (0–4)

1 (0–3)

0.28

Days of antibiotics (median [IQR]), days 1–10

5 (3–8)

6.5 (4–8)

5 (3–8)

0.10

Urine output, days 2–10 (median [IQR] (n = 87; 27; 60)

1125 (725–1701.4)

1110 (691–1635)

1157.9 (732.5–1764.6)

0.42

Worst AVPU, days 2–10 (n,%) (n = 196; 54; 137)

   

1.00

Alert

189 (96.4)

53 (96.4)

136 (96.5)

 

Responds to Voice

7 (3.6)

2 (3.6)

5 (3.5)

 

Responds to Pain

0

0

0

 

Unresponsive

0

0

0

 

Hospital length of stay, days (median [IQR] 1

8 (3–18)

10.5 (6–20)

7 (3–15)

0.013

  1. Numbers in brackets, where provided, refer to the number of patients with data.
  2. 1 Hospital length of stay is calculated as the difference between discharge and admission date. If these dates are equal, it is counted as 1 day.